Antiangiogenic Therapy for Cancer: An Update
- 3 December 2012
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 32 (12) , 1095-1111
Abstract
The idea of antiangiogenic therapy was the brainchild of D r. J udah F olkman in the early 1970s. He proposed that by cutting off the blood supply, cancer cells would be deprived of nutrients and, hence, treated. His efforts paid off when b evacizumab, a monoclonal antibody targeting vascular endothelial growth factor, was approved as antiangiogenic therapy in 2004 for the treatment of colon cancer. Since then, an array of antiangiogenic inhibitors, either as monotherapy or in combination with other cytotoxic and chemotherapy drugs, have been developed, used in clinical trials, and approved for the treatment of cancer. Despite this important breakthrough, antiangiogenic therapy for cancer met with a number of hurdles on its way to becoming an option for cancer therapy. In this article, we summarize the most current information on the mechanisms of tumor angiogenesis, proangiogenic and antiangiogenic factors, potential targets and their mechanisms of action, and experimental evidences, as well as the most recent clinical trial data on antiangiogenic agents for cancer therapy.Keywords
This publication has 98 references indexed in Scilit:
- Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancerBritish Journal of Cancer, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Notch signalling in cancer progression and bone metastasisBritish Journal of Cancer, 2011
- Endothelins and their receptors in cancer: Identification of therapeutic targetsPharmacological Research, 2011
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialThe Lancet Oncology, 2010
- Tie1-Tie2 Interactions Mediate Functional Differences between Angiopoietin LigandsMolecular Cell, 2010
- Integrin and Growth Factor Receptor Alliance in AngiogenesisCell Biochemistry and Biophysics, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Angiogenesis in life, disease and medicineNature, 2005
- The biology of VEGF and its receptorsNature Medicine, 2003